Floatz logo

Ensartinib

Recurrent Non-Hodgkin Lymphoma

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Recurrent Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
Nivolumab
University of Pittsburgh
Phase 2/3BBB
Cediranib
Mayo Clinic
Phase 2BB
5-azacytidine
National Cancer Institute (NCI)
Phase 2BB
Tazemetostat
SWOG Cancer Research Network
Phase 2BB
Ipilimumab
OHSU Knight Cancer Institute
Phase 2BB

View all 20 →

Same molecule, other indications

Ensartinib is also rated in:

MPRDormant
BB
Indicative ·
65 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
63 / 100
View asset →
Neoadjuvant TherapyDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →